IGBA Statement at the Opening of the Sessions at the WIPO Assemblies (July 2024)
Pharmaceutical innovation drives progress, and deserves reward, with intellectual property playing a key role in its protection. Expanding access to these innovations after rewarding them is crucial for public health. In well-functioning markets, generic and biosimilar medicines provide affordable, quality-assured therapeutic options enabling widespread access without compromising safety, efficacy, or quality. This balance supports Universal Health Coverage, reduces financial vulnerability, and ensures sustainable healthcare systems, contributing to Sustainable Development Goals 1, 3, and 10.
